C19orf50 Inhibitors
C19orf50 inhibitors are compounds that affect the activity of the protein C19orf50 by targeting various cellular processes that are upstream or integral to its function. The histone deacetylase inhibitors, such as Trichostatin A, Vorinostat, Entinostat, and Romidepsin, function by increasing histone acetylation, leading to a more relaxed chromatin state. This relaxed state can reduce C19orf50's ability to access and bind to its target DNA sequences within the chromatin, as C19orf50 might preferentially interact with DNA in a more compacted form. The acetylated chromatin structure may also affect the recruitment of co-factors required for C19orf50's activity, further inhibiting its function.
In addition, inhibitors like 5-Azacytidine, RG108, and Decitabine modulate the methylation status of DNA. By inhibiting DNA methyltransferase activity, these compounds decrease DNA methylation levels, which can hinder C19orf50's ability to recognize and bind to its target methylated DNA regulatory regions. This disruption of DNA-protein interactions can lead to decreased functional activity of C19orf50. Proteasome inhibitors such as MG132 may lead to increased levels of proteins that can bind to and sequester C19orf50 or its co-factors, further inhibiting its functional activity. Cell cycle modulation by PD0332991, as well as transcriptional inhibition by Triptolide, represent additional strategies that indirectly lead to a reduction in C19orf50's target gene expression. A-366, targeting histone methylation, may alter the recruitment of C19orf50 to its binding sites.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
A potent protein kinase inhibitor known to broadly target protein kinases, which can lead to the inhibition of phosphorylation events necessary for C11orf52 activation or stability. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3K inhibitor that can downregulate PI3K/Akt signaling, potentially impacting C11orf52 if it's involved in this pathway by inhibiting downstream effects that might stabilize or activate C11orf52. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor which can inhibit the mTOR pathway, potentially reducing protein synthesis of proteins downstream or associated with C11orf52, thus indirectly inhibiting its functional activity. | ||||||
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $63.00 $92.00 $250.00 $485.00 $1035.00 $2141.00 | 69 | |
An immunosuppressant that inhibits calcineurin, thereby potentially impacting the NFAT pathway which could be integral to the functional activity of C11orf52. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
A MEK inhibitor that can inhibit the MAPK/ERK pathway, possibly leading to decreased functional activity of C11orf52 if it relies on this pathway for activation or stability. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A p38 MAPK inhibitor that may lead to reduced activity of C11orf52 if it is modulated by or dependent on the p38 MAPK signaling for its activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of the JNK signaling pathway which could decrease C11orf52 activity if C11orf52 is regulated by JNK-mediated signaling events. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
Another MEK inhibitor that can also downregulate the MAPK/ERK pathway, potentially affecting C11orf52 activity by the same mechanism as PD98059. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
An inhibitor of histone deacetylases (HDACs) which could alter chromatin structure and thus indirectly affect the activity of C11orf52 by changing the expression of genes that regulate C11orf52 or its pathway components. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
A proteasome inhibitor that can lead to accumulation of misfolded proteins, potentially affecting C11orf52 by inhibiting its degradation pathway and leading to cellular stress that indirectly reduces its activity. | ||||||